InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.20
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.00
(
0.64%
)
Bitcoin
60,276.29
(
-2.82%
)
Post# of 252474
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119976
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 106030

Sunday, 10/10/2010 7:37:20 PM

Sunday, October 10, 2010 7:37:20 PM

Post# of 252474

…how do you explain that there exists a Hatch-Waxman 30-month stay both for Momenta's and Natco's generic copaxone with different dates?

Under Hatch-Waxman, each Paragraph-IV challenger for a given branded drug has its own 30-month stay. However, since enactment of the Medicare Modernization Act of 2003, a branded-drug company can obtain only one 30-month stay against a given challenger for a given drug, regardless of how many patents protect the drug in question.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up